Prasugrel Intermediate Metabolite Modulates Platelet Inhibition by Negatively Interfering With an Active Metabolite: An Ex Vivo, In Vitro, and In Silico Study
Prasugrel is converted into prasugrel active metabolite (PAM; R-138727) through the cytochrome P450-mediated conversion of an intermediate metabolite (PIM; R-95913). It is unknown whether PIM exerts any biological function. The FABOLUS-FASTER trial (Facilitation Through Aggrastat or Cangrelor Bolus...
Saved in:
| Published in: | Arteriosclerosis, thrombosis, and vascular biology Vol. 45; no. 5; p. 792 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
01.05.2025
|
| Subjects: | |
| ISSN: | 1524-4636, 1524-4636 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!